Detalhe da pesquisa
1.
Sensitizing protective tumor microenvironments to antibody-mediated therapy.
Cell
; 156(3): 590-602, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24485462
2.
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.
Blood
; 143(6): 522-534, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946299
3.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38620092
4.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 25(6): 744-759, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38821083
5.
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.
Eur J Nucl Med Mol Imaging
; 51(5): 1361-1370, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38114616
6.
Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
Eur J Haematol
; 112(6): 984-987, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38316549
7.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38693677
8.
Management of front line chronic lymphocytic leukemia.
Am J Hematol
; 97 Suppl 2: S3-S10, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36125035
9.
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
Am J Hematol
; 96(9): 1112-1119, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34050972
10.
Specialized palliative care in patients with haematological malignancies receiving chimeric antigen receptor T-cell therapy.
Br J Haematol
; 2024 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38522848
11.
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
Am J Hematol
; 94(9): 1002-1006, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31222797
12.
CLL-IPI: valid in the era of oral inhibitors?
Blood
; 138(2): 106-107, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34264275
13.
Economic evaluation of chronic lymphocytic leukemia from a hospital management perspective.
Eur J Haematol
; 98(2): 169-176, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27727474
14.
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy.
Hemasphere
; 7(1): e817, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36698613
15.
Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy.
Radiother Oncol
; 183: 109580, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36842663
16.
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.
Nat Med
; 29(11): 2844-2853, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37872225
17.
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 22(7): e498-e506, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35094950
18.
miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia.
Blood
; 114(15): 3255-64, 2009 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-19692702
19.
Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease.
Blood
; 112(10): 4213-9, 2008 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18708628
20.
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG).
Hemasphere
; 4(1): e336, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32072150